Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 19, Issue 6, 2008, Pages 413-418

  Sabuda, Deana M ^a,b   Laupland, Kevin ^a,c   Pitout, Johann ^a   Dalton, Bruce ^a,b   Rabin, Harvey ^a,c   Louie, Thomas ^a,c   Conly, John ^a,c,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b CALGARY HEALTH REGION   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d FOOTHILLS HOSPITAL   (Canada)

Author keywords

Colistimethate; Colistin; Intravenous; Metallo betalactamase; Pseudomonas aeruginosa

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE; AZTREONAM; BACLOFEN; CARBAPENEM DERIVATIVE; COLISTIMETHATE; CYCLOSPORIN; FLUDARABINE; GABAPENTIN; METALLO BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TIZANIDINE;

ADULT; AGED; ANOREXIA; ARTICLE; BACTEREMIA; CANADA; CLINICAL ARTICLE; DEMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG FATALITY; DRUG FEVER; DRUG UTILIZATION; FEMALE; HOSPITAL DEPARTMENT; HUMAN; MALE; MEDICAL RECORD REVIEW; MULTIDRUG RESISTANCE; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEBULIZATION; NEPHROTOXICITY; NEUROTOXICITY; PATIENT IDENTIFICATION; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; SOMNOLENCE; TREATMENT DURATION; URINARY TRACT INFECTION;

EID: 58149229311     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/743197     Document Type: Article

References (30)

1. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-8.
2. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005;39:15-20.
3. Kasiakou SK, Fragoulis K, Tzagarakis G, Mistidis P, Kapaskelis A, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii fixation device-related orthopedic infections in two patients with intravenous colistin. Microb Drug Resist 2005;11:287-9.
4. Fulnecky EJ, Wright D, Scheld WM, Kanawati L, Shoham S. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect 2005;51:249-51.
5. Linden P, Kusne S, Coley K, Fontes P, Kramer D, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003;37:154-60.
6. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78-83.
7. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteremia with continuous intravenous infusion of colistin. Scand J Infect Dis 2005;37:142-5.
8. Berlana D, Llop JM, Fort E, Badia MB, Jodar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005;62:39-47.
9. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11.
10. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annual Rev Biochem 1977;46:723-63.
11. Chambers HF. Protein synthesis inhibitors and miscellaneous antibacterial agents. In: Brunton LL, ed. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill Publishing, 2006.
12. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953-8.
13. IMP-7 Antimicrob Agents Chemother 2002;46:255-8.
14. Laupland KB, Parkins MD, Church DL, et al. Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: Importance of metallo-β-lactamase (MBL)-producing strains. J Infect Dis 2005;192:1606-12.
15. Pitout JD, Gregson DB, Poirel L, et al. Detection of Pseudomonas aeruginosa producing metallo-β-lactamases in a large centralized laboratory. J Clin Microbiol 2005;43:3129-35.
16. Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayhall CG, ed. Hospital Epidemiology and Infection Control. Philadelphia: Lippincott Williams & Wilkins, 2004:1659-702.
17. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, Fourteenth Informational Supplement M100-S14. Pennsylvania: The National Commmittee for Clinical Laboratory Standards, 2004.
18. Li J, Nation RL, Turnidge JD. Defining the dosage units for colistin methanesulfonate: Urgent need for international harmonization. Antimicrob Agents Chemother 2006;50:4231-2.
19. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007;51:1905-11.
20. Jancel T, Pitrak D. Colistin for the treatment of multidrug resistant (MDR) gram-negative infections in patients without cystic fibrosis. 44th IDSA Abstracts, Infectious Diseases Society of America, 2006:77. (Abst)
21. Rynn C, Wootton M, Bowker KE, Alan HH, Reeves DS. In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999,5:32-6.
22. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multi-antibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:905-9.
23. Chin JN, Rybak MJ, Cha R, Rhomberg PR, Jones RN. Evaluation of colistin alone or in combination with antimicrobial agents against clinical isolates of carbapenam-resistant P aeruginosa. Program and abstracts of the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, California). Washington, DC: American Society for Microbiology, 2006. (Abst)
24. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. Intavenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997;52:987-93.
25. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 2003;47:2659-62.
26. Horianopoulou M, Lambropoulos S, Papafragas E, Falagas ME. Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis. J Chemother 2005;17:536-8.
27. Li J, Nation RL. Old polymyxins are back: Is resistance close? Clin Infect Dis 2006;43:663-4.
28. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9.
29. Falagas ME, Rafailidis PI. When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach. Shock 2007;27:605-9.
30. Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007;30:525-9.